Opinion

Video

Long-term Safety Data for JAK Inhibitors in Atopic Dermatitis

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Video content above is prompted by the following:

  1. Please discuss phase 3 and long-term efficacy (International Global Assessment scores, Eczema Area and Severity Index scores, itch relief) and safety data for abrocitinib and upadacitinib in atopic dermatitis (AD).
  2. How do the long-term data affect your decision to use oral JAK inhibitors in AD?
  3. Do you have any safety concerns that have not been addressed by the long-term data so far?
Related Videos
Safety Profile, Accessibility of Tapinarof Cream for Atopic Dermatitis, with Adelaide Hebert, MD
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Sobia Laique, MD | Credit: Cleveland Clinic
Sobia Laique, MD | Credit: Cleveland Clinic
What is the Global Lung Function Initiative and Its Purpose for Lung Function Testing?
Greg A. Sachs, MD I Credit: Regenstrief Institute
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.